RIPK2 and inflammatory breast carcinoma: Analysis of pre-chemotherapy tissue sections from IBC patients lead to two novel observations: (i) RIPK2 activity may be a contributory mediator to inflammation post-neoadjuvant chemotherapy and (ii) neoadjuvant chemotherapy may not necessarily lead to a decrease from the pre-chemotherapy levels of RIPK2 and thus may not be the ideal single mode of therapy to reduce inflammation and the proliferative effects of inflammation.